Cypen Jeremy, Ahmad Tariq, Testani Jeffrey M, DeVore Adam D
Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA.
Curr Heart Fail Rep. 2017 Oct;14(5):434-443. doi: 10.1007/s11897-017-0358-4.
The use of biomarkers in heart failure (HF) is a rapidly changing field. The purpose of this review is to assess the current evidence of the use of biomarkers for risk stratification in patients with HF with preserved ejection fraction (HFpEF).
Despite differences in pathophysiology between HF with reduced ejection fraction and HFpEF, traditional HF biomarkers such as brain natriuretic peptide and troponin retain prognostic value in most HFpEF-specific populations. Biomarkers of key pathophysiologic components of HFpEF, such as myocardial fibrosis, remodeling, and systemic inflammation are also valuable prognostic markers. Further investigation into HF biomarkers may identify significant therapeutic targets for the treatment of HFpEF.
生物标志物在心力衰竭（HF）中的应用是一个快速发展的领域。本综述旨在评估目前使用生物标志物对射血分数保留的心力衰竭（HFpEF）患者进行风险分层的证据。
尽管射血分数降低的心力衰竭和HFpEF在病理生理学上存在差异，但传统的HF生物标志物如脑钠肽和肌钙蛋白在大多数HFpEF特异性人群中仍具有预后价值。HFpEF关键病理生理成分的生物标志物，如心肌纤维化、重塑和全身炎症，也是有价值的预后标志物。对HF生物标志物的进一步研究可能会确定HFpEF治疗的重要治疗靶点。
